Researchers at the UCL Institute of Immunity and Transplantation (IIT) have discovered that a single gene plays an important role in ensuring humans are able to fight infections. More...
The Institute focusses on “bench to bedside” translational research to develop vaccinations, gene therapy and cell therapy to target immune-related conditions, as well as new types of transplant. Clinical areas include:
- cancer and leukaemia
- chronic infections such as HIV, viral hepatitis and tuberculosis
- auto-immune diseases including diabetes, scleroderma and inflammatory bowel disease
- inherited immunodeficiency
- other rare diseases such as haemophilia and amyloidosis
- tissue and organ transplantation.
Specific projects to improve early diagnosis and therapeutic options include:
- Successful development of gene therapy for haemophilia B, and expanding this to other forms of haemophilia and to lysosomal storage diseases.
- Improviding leukaemia immunotherapy through new lentiviral-vector vaccines targetting skin dendritic cells.
- Developing new vaccination protocols to prevent viral disease in transplant patients
- Adoptive cell therapy for leukaemia/lymphoma and viral infection
- Innovative gene therapies for leukaemia, solid cancers and chronic infection
- Discovering the genetic basis of certain forms of immunodeficiency and autoimmune conditions such as inflammatory bowel disease, facilitating early diagnosis and treatment
- New biological therapies for patients with scleroderma, rheumatoid arthritis and pulmonary arterial hypertension
- Tissue engineering and artificial organs for transplantation
- Immune therapy for type 1 diabetes
- Immune regulation and transplantation immunity
- Hepatitis C virus cell-entry and antibody modulation.
Page last modified on 29 jul 13 15:33